Redeye comments on the Q4 report released earlier this morning.
Redeye comments on Raketech’s preannounced Q4-results which were lower than expected while the compa...
Navamedic ASA (”Navamedic” or ”the Company”) is a Nordic pharmaceutical company offering a diversifi...
Redeye maintains its fair value range for Sleep Cycle following the Q4 2024 report, which met our sa...
Sales and gross margin above expectations in Q4 EBIT revised up by 2.
Probi avslutar sin 20-åriga resa på börsen – detta med flaggan i topp.
Redeye provides initial comments on Sleep Cycle’s Q4 report, in which sales were in line with expect...
Redeye sees another strong quarter for OssDsign as sales beat our estimates with a continuing robust...
Raute reports Q4 results on Feb 13. FY’24 already showed strong results, while low valuation limits ...
We anticipate Vaisala’s profitable growth journey to take a leap in 2025 aided by acquisitions.
Etteplan reports its Q4 figures on 12th of February.
Redeye is encouraged by the healthy rebound in demand witnessed in Ependion’s Q4 report.
Ahead of Taaleri's Q4 results, we revise our underlying estimates to reflect Taaleri's sale of its s...
Medical has stabilised following a period of volatile margins More margin expansion left, Medical to...
Consti reports its Q4 result on 7th of February. We anticipate slight sales growth for Q4, although ...
Dovre completed its segmental sale for a significant cash pile, the eventual use of which remains an...
SRV reports its Q4 figures on 6th of February. We expect slight improvement in adj.
NanoEcho är ett medicintekniskt bolag som utvecklar ett innovativt bildgivande system för tydligare ...
Q4 markerar en sval avslutning på året och Coor har flaggat för pressade marginaler mot bakgrund av ...
Redeye comments on the ongoing launch in Norway of Terclara.
